Property | Value |
Name | Role of CYP2C9 and VKORC1 polymorphism in dose dependent Warfarin therapy management |
Description | Research article 3Clinical Pathology Department, Faculty of Medicine, Alexandria University Faculty of Medicine, Alexandria University, Egypt. 4Resident in Clinical Pathology Department, Faculty of Medicine, Alexandria University, Egypt.
References:
1.Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(1 suppl):8S.Pubmed 2.Bernard JM BJ, Kokseng CU.et al. Warfarin sodium.Practitioner beware. AmPodiatr Med Assoc. 1992;82:345.Pubmed 3.Brummel KE, Paradis SG, Branda RF, Mann KG. Oral anticoagulation thresholds. Circulation. 2001;104(19):2311.Pubmed 4.Schelleman H, Limdi NA, Kimmel SE. Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics.2008;9(9):1331-46.Pubmed 5.Chow W , Chow T , Tse T , Tai Y , Lee W . Anticoagulation instability with life threatening complication after dietary modification. Postgraduate medical journal . 1990; 66(780):855.Pubmed 6.Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC. Interaction between warfarin and Panax ginseng in ischemic stroke patients. The Journal of Alternative and Complementary Medicine. 2008;14(6):715-21.Pubmed 7.Zhao F, Loke C , Rankin S.C , Guo J.Y, Lee H.S , Wu T.S , et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004;76:210–9.Pubmed 8.Rane A, Lindh JD. Pharmacogenetics of anticoagulants. Hum Genomics Proteomics. 2010 Sep 13;2010:754919. doi: 10.4061/2010/754919.Pubmed 9.Krynetskiy E, McDonnell P. Building individualized medicine: prevention of adverse reactions to warfarin therapy. Journal of Pharmacology and Experimental Therapeutics. 2007;322(2):427.Pubmed 10.Majerus P, Broze G, Miletich J, Tollefsen D. Anticoagulant, thrombolytic, and antiplatelet drugs. Goodman and Gilman’s The pharmacological basis of therapeutics. 1995:1341-59. 11.Zhang K, Young C, Berger J. Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions. Journal of Managed Care Pharmacy. 2006;12(8):640.Pubmed 12.Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Annals of Internal Medicine. 1997;126(2):133.Pubmed 13.Lamb GC. Loading Dose and Monitoring of Warfarin Therapy-Reply. JAMA: The Journal of the American Medical Association. 1997;278(7):548.Pubmed 14.Kovacs MJ, Rodger M, Anderson DR, Morrow B, Kells G, Kovacs J, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. Annals of Internal Medicine. 2003;138(9):714.Pubmed 15.Fennerty A, Campbell I, Routledge P. Anticoagulants in venous thromboembolism. British Medical Journal. 1988;297(6659):1285.Pubmed 16.Smellie WSA, Hampton K, Bowlees R, Martin S, Shaw N, Hoffman J, et al. Best practice in primary care pathology: review 8. Journal of clinical pathology. 2007;60(7):740.Pubmed 17.Lenzini PA, Grice GR, Milligan PE, Dowd MB, Subherwal S, Deych E, et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. Journal of Thrombosis and Haemostasis. 2008;6(10):1655-62.Pubmed 18. Bennett S. Monitoring Anticoagulant Therapy. Laboratory Hemostasis. 2007:167-205.Link 19.Schulman S. Care of patients receiving long-term anticoagulant therapy. N Engl J Med. 2003 Aug 14;349(7):675-83..Pubmed 20.Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. The Journal of Clinical Pharmacology. 2005;45(2):127.Pubmed 21.Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. Journal of thrombosis and thrombolysis. 1998;5:19-24.Pubmed 22.Ansell J, Jacobson A, Levy J, Völler H, Hasenkam JM. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. International journal of cardiology. 2005 Mar 10 ;99(1):37-45.Pubmed 23.Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005 Oct 1;106(7):2329. Pubmed 24.Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1--Rationale and perspectives. Thrombosis research. 2007;120(1):1-10.Pubmed 25. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet (TM) systematic review and meta-analysis. Genetics in Medicine. 2005;7(2):97.Pubmed 26.Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clinical pharmacokinetics. 2001;40(8):587-603. 27.Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature. 2004;427(6974):541-4.Pubmed 28.Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427(6974):537-41.Pubmed 29.Oldenburg J. VKORC1: the little big protein. Blood. 2005;106(12):3683.Link 30.Flockhart DA, O’Kane D, Williams MS, Watson MS, Gage B, Gandolfi R, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genetics in Medicine. 2008;10(2):139.Pubmed 31.Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med.2008;358(10):999-1008.Pubmed 32.Loebstein R, Yonath H, Peleg D , Almog S, Rotenberg M , Lubetsky A , et al. Interindividual variability in sensitivity to warfarin—nature or nurture? Clin Pharmacol Ther. 2001;70:159–64.Pubmed 33.Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV. et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009 Jan;40(1):235-40.Pubmed 34.Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E,et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost. 2005;94(4):773-9.Pubmed 35. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE . Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002 Apr 3;287(13):1690-8.Pubmed 36.Vecsler M LR, Almog S, Kurnik D, Goldman B, Halkin H, Gak E. Combined genetic profiles of components and regulators of the vitamin K dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost. 2006;95:205-11.Pubmed 37.Takahashi H, Wilkinson G.R, Caraco Y, Muszkat M, Kim R.B., Kashima T, et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther. 2003;73:253–63.Pubmed 38.Hill CE, Duncan A, Wirth D, Nolte FS. Detection and identification of cytochrome P-450 2C9 alleles *1, *2, and *3 by high-resolution melting curve. Am J Clin Pathol. 2006;125:584-91.Pubmed 39.Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther.2008;84(3):326-31.Pubmed 40.Hamdy SI, Hiratsuka M, Narahara K, Endo N, ElEnany M, Moursi N, et al. Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. British journal of clinical pharmacology. 2003;55(3):321-4.Pubmed 41.Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics. 2010;1(6):781-91.Pubmed 42.Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance&ast. Clinical Pharmacology & Therapeutics. 2002;72(6):702-10.Pubmed 43.Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes&ast. Clinical Pharmacology & Therapeutics. 1998;63(5):519-28. 44.Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 2000;96(5):1816-9.Pubmed 45. Limdi N, McGwin G, Goldstein J, Beasley T, Arnett D, Adler B, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clinical Pharmacology & Therapeutics. 2007;83(2):312-21.Pubmed 46. Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Current clinical pharmacology. 2007;2(1):93-109.Pubmed 47.Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics. 2007;8(11):1545-50.Pubmed 48.Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Current clinical pharmacology. 2007;2(1):93-109.Pubmed 49. Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K, Kurabayashi M, et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients&ast. Clinical Pharmacology & Therapeutics. 2006;80(2):169-78.Pubmed 50.Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. The pharmacogenomics journal. 2003;3(4):202-14.Pubmed 51.Moyer TP, O'Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience Mayo Clin Proc. 2009 Dec;84(12):1079-94. doi: 10.4065/mcp.2009.0278.Pubmed 52.Yuan HY, Chen JJ, Lee MTM, Wung JC, Chen YF, Charng MJ, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Human molecular genetics. 2005;14(13):1745-51.Pubmed 53.Xie HG, Prasad H.C, Kim R.B. and Stein C.M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Delivery Rev.54:1257–70.Pubmed 54.Elizabeth A. Sconce, Tayyaba I. Khan, Hilary A. Wynne, Peter Avery, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirement: proposal for a new dosing regimen. Blood. 2005;106:2329–33.Pubmed 55.Sanderson S , Emery j, Higgins J . CYP29 gene variants , drug dose ,and bleeding risk in warfarin treated patients: HuGent ™ systematic review and metaanalysis . Genetics in Medicine .2005; 792):97.Pubmed 56. Mark J. Rieder, Alexander P. Reiner, Brian F. Gage, Deborah A, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285–93.Pubmed 57. Rost S, Fregin A, Ivaskevicius V, Conzelmann E , Hortnagel K, Pelz H.J , et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427:537–41.Pubmed 58. Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin&ast. Clinical Pharmacology & Therapeutics. 2004;75(3):204-12.Pubmed 59.Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA: The Journal of the American Medical Association. 2002;287(13):1690-8.Pubmed 60.Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenestra DL. An analysis of the relative effects of VKORC1 and CYP2C9 variants on. ThrombHaemost. 2008;100:220–39.Pubmed 61.Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New England Journal of Medicine. 2005;352(22):2285-93.Pubmed 62. Tatarūnas V, Lesauskaitė V, Veikutienė A, Jakuška P, Benetis R. The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on Optimal Warfarin Doses After Heart Valve Replacement. Medicina (Kaunas). 2011;47(1):25-30.Pubmed 63.Gan GG, Phipps ME, Lee MMT, Lu LS, Subramaniam RY, Bee PC, et al. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. Annals of Hematology. 2011;90(6):635-41.Pubmed 64.H Echizen H Ta. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics.2003;3:202–14.Pubmed 65.Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010 May 6;115(18):3827-34.Pubmed 66.Ensom MHH, T. K. H. Chang , and P. Patel. Pharmacogenetics: the therapy drug monitoring of the future? Clin Pharmacokinet. 2001;40:783–802.Pubmed 67.Dorothy M. Adcock CK, Domnita Crisan and Frederick L. Kiechle. Effect of Polymorphisms in the Cytochrome P450 CYP2C9 Gene on Warfarin Anticoagulation. Archives of Pathology & Laboratory Medicine. 2004 December;128(12):1360-3.Pubmed 68.Mannuci PM. Genetic control of anticoagulation. Lancet. 1999;353:688–9.Pubmed 69.Poller I A .Mckernan, J M Thomson and M Elstein . Fixed mini dose warfarin:a new approach to prophylaxis against venous thromboembolism after major surgery .Br Med J. 1987; 295:1309-12.Pubmed
Article citation:- |
Filename | Nermine Hossam Zakaria(1468-1485.).pdf |
Filesize | 1.01 MB |
Filetype | pdf (Mime Type: application/pdf) |
Creator | admin |
Created On: | 08/07/2013 00:00 |
Viewers | Everybody |
Maintained by | Editor |
Hits | 4326 Hits |
Last updated on | 10/10/2013 12:09 |
Homepage | |
CRC Checksum | |
MD5 Checksum |